Pegcetacoplan Effective in Real-World Setting for CI-Naive, CI-Experienced PNH Patients Researchers compared the response to pegcetacoplan therapy at treatment initiation and at the time of surveying CI-experienced vs CI-naive patients.

Treatment with #Pegcetacoplan has demonstrated significant improvements in hematologic parameters in both #ComplementInhibitor (CI)-experienced and CI-naive patients with #PNH in real-world clinical settings across Europe and Canada.

Learn more: https://bit.ly/4a12G9s

Omeros Corporation - Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA The Investor Relations website contains information about Omeros Corporation's business for stockholders, potential investors, and financial analysts.

Omeros announces robust improvement in survival for #narsoplimab expanded access program in #TA-TMA over external control. More info: shorturl.at/NA9fy #complementinhibitor #omeros

Omeros Corporation - Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint The Investor Relations website contains information about Omeros Corporation's business for stockholders, potential investors, and financial analysts.

Omeros announces newly completed sensitivity analyses demonstrating robustness of previously announced survival superiority over external control in #TA-#TMA More info: investor.omeros.com/news-release... #narsoplimab #complementinhibitor #omeros